

# CURRICULUM VITAE

## Syed A. Rizvi, M.D

Business Address: Neurology Foundation, Inc.  
2 Dudley Street, Suite 555  
Providence, RI 02905

Business Telephone: 401-444-3799  
Fax: 401-444-3205  
Email: [srizvi@lifefspan.org](mailto:srizvi@lifefspan.org)

### EDUCATION

Undergraduate: D.J Science College, Karachi, Pakistan 1982-1984

Medical School: M.B.B.S, Dow Medical College 1985-1991  
Karachi, Pakistan  
*Distinction in Pharmacology*  
*Wyeth Gold Medal in Surgery*  
*Certificate of Honor*

ECFMG 1992

FLEX 1992

### POSTGRADUATE TRAINING

Medical Internship: Atlantic City Medical Center 1992-1993  
Atlantic City, NJ

Residency: Combined Internal Medicine and 1993-1997  
Neurology  
Stony Brook University Hospital  
Stony Brook, NY

Chief Resident: Internal Medicine 1997-1998  
Stony Brook University Hospital  
Stony Brook, NY

Fellowship: Neuroimmunology/Multiple Sclerosis 1998-1999  
Stony Brook, NY

## **PROFESSIONAL LICENCES AND BOARD CERTIFICATION**

Diplomate, American Board Psychiatry and Neurology	1999
Diplomate, American Board of Internal Medicine	1997
Medical License: State of Rhode Island #10697	2001

## **ACADEMIC APPOINTMENTS**

Assistant Instructor in Neurology, Stony Brook University Hospital	1993-1997
Assistant Professor, Department of Neurology, Stony Brook University Hospital, Stony Brook, NY	1999-2001
Assistant Professor, Department of Clinical Neurosciences, Brown Medical School, Providence, RI	2002-present

## **HOSPITAL APPOINTMENTS**

Attending Neurologist, Rhode Island Hospital, Providence, RI	2002-present
Consulting Neurologist, Women and Infants Hospital, Providence, RI	2002-present
Consulting Neurologist, Newport Hospital, Newport, RI	2002-present

## **OTHER APPOINTMENTS**

Chairman, Clinical Advisory Committee, Multiple Sclerosis Society, RI Chapter	2002-present
Research Advocate, National Multiple Sclerosis Society	2002-present
Member, Board of Trustees, Multiple Sclerosis Society	2002-present
Director, Rhode Island Hospital Multiple Sclerosis Clinic	2004-present
Infection Control Committee, RIH	2006-present

## **MEMBERSHIP IN SOCIETIES**

American Academy of Neurology	1998-present
National Multiple Sclerosis Society	1999-present
MS Consortium	- present
American Academy of Immunotherapy	- present
Rhode Island Medical Society	- present

## **ORIGINAL PUBLICATIONS IN PEER REVIEWED JOURNALS**

Krupp LB, **Rizvi SA**, “Symptomatic therapy for under-recognized manifestations of multiple sclerosis.” *Neurology* 2002;58:S32-S39.

Malik K, **Rizvi S**, Vaillancourt PD, “The SUNCT Syndrome: Successfully Treated With Lamotrigine.” *Pain Med* 2002, Jun;3(2):167-8.

**Rizvi SA**, Bashir K, Khurram, “Other therapy options and future strategies for treating patients with multiple sclerosis.” *Neurology* 2004;63:S47-54.

Cohen BA, Khan O, Jeffery DR, Bashir K, **Rizvi SA**, Fox EJ, Agius M, Bashir R, Collins TE, Herndon R, Kinkel P, Mikol DD, Picone MA, Rivera V, Tornatore C, Zwibel H, “Identifying and treating patients with suboptimal responses.” *Neurology* 2004;63:S33-40.

**Rizvi SA**, Zwibel H, Fox EJ, “Mitoxantrone for multiple sclerosis in clinical practice.” *Neurology* 2004;63:S25-27.

**Rizvi SA**, Agius MA, “Current approved options for treating patients with multiple sclerosis,” *Neurology* 2004;63:S8-14.

Mellion M, **Rizvi SA**, “Spontaneous bilateral carotid artery dissection and posterior reversible encephalopathy syndrome.” *Neurology*, Dec 2005;65:1990.

**Rizvi SA**, Kim E, Moodie J, Glatiramer in the treatment of Multiple sclerosis. *International Journal of Nanomedicine* 2006: 1 (3)

**RIZVI SA**, “Multiple Sclerosis: Current and Future Treatment Options” *Endocrine , Metabolic & Immune Disorders-Drug Targets* Volume 7, Issue 4, December, 2007

## **OTHER NON-PEER REVIEWED PUBLICATIONS**

Coyle PK, **Rizvi SA**, “A Global Perspective on Multiple Sclerosis,” Medscape summary, XVII World Congress of Neurology, 2001.

Participant, “Use of Neutralizing antibody assays in MS patients,” consensus statement, Boston, MA, September 11, 2003.

## **WEBCAST**

“Treatment of acute Multiple Sclerosis relapses” CME, Post graduate institute of medicine, 2006. MSLeaders.org

“Management of the breakthrough patients”. CME, Post graduate institute of medicine, 2006. MSLeaders.org

## **ABSTRACTS**

Coyle PK, **Rizvi SA**, Melville PM, “Symptomatic Early Lyme Disease in Adults,” Ann Neurol 1999;46:488.

Coyle PK, **Rizvi SA**, Bernal O, “Neurologic Involvement in Early Lyme Disease,” Neurology 2000(suppl.3);54(7):A157-A158.

**Rizvi SA**, Robertson S, Krupp LB, Coyle PK, “To Assess the Benefits of Brief Bed Rest on Post Dural-Puncture Headache (PDPH),” Neurology 2000;54:A423.

Elkins L, Krupp LB, Smirolido J, **Rizvi SA**, Coyle PK, “Brief Cognitive Screening in Multiple Sclerosis: Mini-mental examination and the Clock Drawing Test,” AAN, 2000.

Ravi Y, Hasan M, **Rizvi SA**, Coyle PK, “Neurologic Lyme Disease presenting as Incomplete Transverse Myelitis: Clinical and MRI findings,” Neurology 2001;56(suppl3):A479.

Beitinjaneh F, **Rizvi SA**, Coyle PK, Krupp LB, “Diagnostic accuracy of serologic testing for Lyme disease,” Neurology 2001;56(suppl 3):A479-A480.

Krupp LB, Christodoulou C, Elkins L, Coyle PK, **Rizvi SA**, “Designing Clinical Trials for Treating MS-Associated Cognitive Impairment,” Multiple Sclerosis 2001;412.

Coyle PK, **Rizvi SA** Taylor M, Deng Z, “Acute Lyme disease in Northern America: Neurologic Aspects,” Neurology 2002 (suppl 3);58(7):A262.

**Rizvi S**, Asif M, Crabtree B, “A retrospective analysis of safety and efficacy of mitoxantrone in patients with worsening multiple sclerosis,” for AAN 2005.

## **CORPORATE AUTHORSHIP**

L B. Krupp, L. G. Hyman, R. Grimson, P. K. Coyle, P. Melville, S. Ahnn, R. Dattwyler and B. Chandler Study and treatment of post Lyme disease (STOP-LD): A randomized double masked clinical trial. *Neurology* 2003;60:1923-1930 **SUB-INVESTIGATOR**

Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. *Neurology*. Nov 26 2002;59(10):1496-506 **SUB-INVESTIGATOR**

## **PUBLICATIONS SUBMITTED**

“Neurologic complications of lyme disease”. Rhode Island Monthly Magazine (Feb 2008)

## **INVITED PRESENTATIONS**

1. “Medical Malpractice,” *Neurology Grand Rounds*, Stony Brook Hospital, Stony Brook NY 1996
2. “How to get a stroke at a young age,” *Neurology Grand Rounds*, Stony Brook NY 1997
3. “MRI as living pathology in MS,” *Neurology Grand Rounds*, Stony Brook NY 2000
4. “Pathogenesis and treatment of Acute Ischemic Stroke,” *Neurology Grand Rounds* 2001
5. “CNS Infections,” *Neuroscience course lecture*, annually 1999-2001
6. “Neuroimmunology,” *Neuroscience course lecture*, Brown Medical School 2002-yearly
7. “Symptomatic treatment of MS,” Patient Program for TEVA, West Warwick RI 2002
8. “Treatment of Multiple Sclerosis,” Patient Program, Newport Marriot, Newport RI 2002
9. “Immunology and Treatment of MS,” *Grand Rounds*, Rhode Island Hospital 2002
10. “Combination Treatment,” Patient Program, MS society, Cranston Library, RI 2002
11. “Multiple Sclerosis Update,” *Grand Rounds*, Roger Williams Hospital, Providence RI 2002
12. “Multiple Sclerosis and Cognition,” *Grand Rounds*, Butler Hospital, Providence RI 2003

13. "Headache: case studies," Noon Conference, Department of Medicine, Rhode Island Hospital 2003
14. "Demyelinating Diseases," Neuroscience course lecture, Brown Medical School 2003
15. "Multiple Sclerosis Update," Grand Rounds, Newport Hospital, Newport RI 2003
16. "Combination Treatment," Patient Program, Newport Hospital, Newport RI 2003
17. "Current Issues in MS," Faculty presentation for Teva Neurosciences, Newport RI
18. "Multiple Sclerosis," Patient presentation for Biogen, Providence RI Sept 13, 2003
19. "Treatment of worsening MS," presentation for Serono, Chatham MA Oct 4, 2003
19. "Breakthrough Disease," presentation for Biogen, Hartford CT Nov. 8, 2003
20. "Novantrone," presentation for Serono, Boston MA Nov 2003
21. "Case presentation," Neurology Grand Rounds, Rhode Island Hospital Dec17, 2003
22. "Novantrone in Clinical Practice," presentation for Serono, Miami FL Jan 9, 2004
23. "Advancing Trends in Multiple Sclerosis," Chair, CME program, Mohegan Sun, Uncasville CT Jan 31, 2004
24. "Overview of Mitoxantrone," presentation for Serono, Miami FL March 6, 2004
25. "Newly Diagnosed MS," Patient Program for MS Society, Providence RI March 20, 2004
26. "Multiple Sclerosis," Noon conference, Department of Medicine, Rhode Island June 7, 2004
27. "AAN update," presentation for Serono, Gatehouse Restaurant, Providence RI July 15, 2004
28. "MS update," Patient Program for MS Society, Newport Hospital, Newport RI Sept 17, 2004
29. "Multiple Sclerosis," presentation for Biogen, Cambridge MA Nov 16, 2004
30. "Tumefactive MS," Neurology Grand Rounds, Rhode Island Hospital Nov 24, 2004
31. "Multiple Sclerosis," presentation for Biogen, Cambridge MA Dec 14, 2004
32. "Tysabri," presentation for Biogen Feb 12, 2005
33. "Tysabri," Neurology Grand Rounds, Rhode Island Hospital March 2, 2005
34. "Meningitis," Department of Medicine Grand Rounds, Rhode Island Hospital Mar. 22, 2005

35. "Research in MS," Berlex Fair, Crown Plaza Hotel, Warwick RI April 2, 2005
36. "Multiple Sclerosis," Seminar for MS Society, Providence RI May 11, 2005
37. "Use of Mitoxantrone," Faculty presenter for Serono, Newport RI June 24, 2005
38. "Five unusual cases," Neurology Grand Rounds, Rhode Island Hospital Sept 21, 2005
39. "MRI in MS," Faculty moderator - CME program, Providence, RI Oct 26, 2005
40. "Overview of MS," CME resident seminar, Foxwood Casino, CT Nov 19, 2005
41. "Spasticity," presentation for Medtronics, Providence RI Jan 18, 2006
42. "MS symptoms," residents' program, TEVA, Providence RI Jan 19, 2006
43. "Genetics in MS," Program for MS Society, Providence RI Jan 26, 2006
44. "Early treatment of MS" Serono, Brockton, MA Mar. 2, 2006
45. "Importance of early treatment of RRMS" Providence, RI, Berlex Jun. 8, 2006
46. "Dural AV fistula" Neurology Grand rounds, RIH Sept 6, 2006
47. "Early treatment of MS" Serono, Manchester, NH Sept 20, 2006
48. "Natalizumab" Biogen, Providence, RI OCT 5, 2006
49. "What every should know about MS" MS society annual meeting Oct 19, 2006
50. "Resident guide to MS" Mohigan sun, CT, Teva Oct 28, 2006
51. "Multiple Sclerosis" Grand Round Roger William Hospital" Oct 31, 2006
52. "Update on Multiple Sclerosis". International Neurol conf., Karachi Pakistan Dec 24, 2006
53. "BENEFIT study" Berlex, Providence, RI Mar 20, 2007
54. "Early treatment of MS" Serono, RI May 3, 2007
55. "Medical Marijuana" Program planner, Brown University CME May 3, 2007
56. "Point Counterpoint" Serono, RI May 9, 2007
57. "New Options in MS treatment" Biogen, RI May 16, 2007
58. "Ask the experts" TEVA, RI May 24, 2007

59 “ Crossfire” <u>MS society</u> , Providence, RI	June 7, 2007
60 “ Multiple sclerosis” MS society, Providence RI	June 13, 2007
61 “ Treatment Of MS” <u>Faculty CME</u> , Providence RI	July 11, 2007
62 “ Advisory Board program” Bayer, Hartford, CT	July 19, 2007
63 “ Future of MS treatment” <u>Grand round</u> Boston University	Sept 04, 2007
64 “ Primary Progressive MS” <u>Grand Round</u> presentation RIH	OCT 17, 2007
65 “ MS Jeopardy” <u>MS Society</u> , Providence, RI	Oct 29, 2007
66 “ Overview of MS” ( <u>Faculty</u> ) <u>MS seminar for residents</u> , CME, Boston	Nov 17, 2007
67 “ ECTRIMS update” TEVA, RI	Nov 16, 2007
68 “ CNS complications of Lyme disease” <u>Grand round</u> presentation RIH	Feb 27, 2008

## **RESEARCH STUDIES**

1. Sub-investigator 1996-2001  
NIH #2R01 AI 31561-04AI  
Chronic Fatigue in Lyme Disease
2. Sub-investigator 1998-2000  
NIH \$5,300,000  
CNS invasion in early B. Burgdorferi infection
3. Co-investigator 1999-2001  
\$115,000  
Neurobehavioral Syndromes of Chronic Lyme Disease
4. Local Co-investigator 2000-2001  
Serono \$551,000  
Multicentre, randomised, assessor-blinded trial.

677 patients with Relapsing/Remitting MS - 339 received Rebif, 44 mcg three times weekly and 338 received Avonex, 30 mcg once weekly for 48 weeks.

- |     |   |                           |
|-----|---|---------------------------|
| 5.  | Co-investigator<br>NIH<br>Interventions to improve memory in MS   | 2000-2002<br>\$485,000    |
| 6.  | Co-investigator<br>Biogen Idec, Inc. and Cephalon<br>Use of Avonex to determine Neurobehavioral Correlates of Fatigue   | 1999-2002<br>\$115,000    |
| 7.  | Local Sub-investigator<br>TEVA<br>Phase III placebo-controlled trial of Oral Glatiramer Acetate   | 2000-2001                 |
| 8.  | Sub-investigator<br>TEVA<br>Promise trial: use of Glatiramer Acetate in Primary Progressive MS  | 2000-2002                 |
| 9.  | Sub-investigator<br>SCIREX<br>Phase II study of Hu23F2G in acute exacerbations of MS  | 1997-2000<br>\$150,000    |
| 10. | Sub-investigator<br>Department of Defense<br>Evaluation of Desert Storm Syndrome  | 1996-1998<br>\$230,000    |
| 11. | PI<br>Biogen<br>Avonex and Novantrone combination study<br><br>Study of the safety and efficacy of combination treatment with Avonex and Novantrone in the treatment of multiple sclerosis, project# 5573 | 2003<br>\$250,000         |
| 12. | Local PI<br>Genentech<br>Phase II/III, Randomized, Double blinded, Placebo controlled Multicenter Study to Evaluate Safety and efficacy of Rituxamab in Adults with PPMS, project # 6267                  | 2004-present<br>\$295,101 |

13. Local PI 2004-2008  
 Berlex \$324,687  
 BEYOND Study: International, randomized, multicenter, phase III study in patients with relapsing-remitting multiple sclerosis comparing over a treatment period of 104 weeks
- Double-blinded - the safety, tolerability, and efficacy of Betaseron/Betaferon 250 µg (8 MIU) and Betaseron/Betaferon 500 µg (16 MIU), both given subcutaneously every other day.  
 Rater-blinded - safety, tolerability, and efficacy of Betaseron/Betaferon s.c. e.o.d. with Copaxone 20 mg s.c. once daily.
14. Local PI 2003-2006  
 Berlex \$198,801  
 A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron® 250µg Subcutaneously Every Other Day with Avonex® 30µg Intramuscularly Once per Week in Relapsing-Remitting Multiple Sclerosis Patients Previously Treated with Avonex®  
 Protocol 307245B, project# 5556
15. Local PI 2003-2006  
 Biogen \$105,600  
 Combination study in RRMS, A multi-center, randomized, blinded, parallel-group study of Avonex® compared with Avonex® in combination with oral methotrexate, intravenous methylprednisolone, or both in subjects with relapsing-remitting multiple sclerosis who have breakthrough disease on Avonex® monotherapy, project # 5736
16. Local PI 2005-present  
 NIH \$63,291/yr  
 Interventions to Improve Memory in Patients with Multiple Sclerosis
17. Local PI 2005-present  
 TEVA \$20,743/per patient  
 A multi-center, randomized, double-blinded, placebo-controlled study assessing add-on effect of oral steroids in relapsing-remitting multiple sclerosis subjects treated with Glatiramer Acetate
18. Local PI 2006-2007  
 Biogen-Idec \$1559/per patient  
 Antibodies on Interferon Responsive Genes Highlights Biomarker Response (INSIGHT)
19. Local PI 2006-present  
 TEVA  
 Double dose Copaxone Study

- |    |   |              |
|----|---|--------------|
| 20 | Local PI<br>Bio-MS<br>“A Double-Blind, Placebo Controlled Multi-Center Study To Evaluate The Efficacy and Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis”  | 2007-present |
| 21 | Local PI<br>Biogen<br>“ A Randomized, Multicenter, Double Blinded, Placebo Controlled, dose Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing Remitting Multiple Sclerosis.”  | 2007-present |
| 22 | Local PI<br>UCB Pharma<br>“ Double-Blinded, Placebo-Controlled, Randomized, Parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis to evaluate the safety, tolerability and effects of two doses of CDP323 over 24 weeks with a rater-blindedMRI follow-up over 12 weeks. | 2007-present |
| 23 | Local PI<br>Biogen<br>“ TYGRIS: Tysabri Global Observational Program in Safety”   | 2007-present |

**UNIVERSITY TEACHING ROLES**

Stony Brook Medical School, Neuroscience course	1999-2001
Brown Medical School, Neurosciences 262 course Lecturer and small group leader	2002-present

**HOSPITAL TEACHING ROLES**

Stony Brook Medical Center, Ward and consult attending	1999-2001
Rhode Island Hospital, Ward and consult attending 3 months/year	2002-present
Teaching attending during resident Clinic rotation	2002-present

